163 related articles for article (PubMed ID: 38100899)
1. Immunomodulator use, risk factors and management of flares, and mortality for patients with pre-existing rheumatoid arthritis after immune checkpoint inhibitors for cancer.
McCarter KR; Arabelovic S; Wang X; Wolfgang T; Yoshida K; Qian G; Kowalski EN; Vanni KMM; LeBoeuf NR; Buchbinder EI; Gedmintas L; MacFarlane LA; Rao DA; Shadick NA; Gravallese EM; Sparks JA
Semin Arthritis Rheum; 2024 Feb; 64():152335. PubMed ID: 38100899
[TBL] [Abstract][Full Text] [Related]
2. Mortality and immune-related adverse events after immune checkpoint inhibitor initiation for cancer among patients with pre-existing rheumatoid arthritis: a retrospective, comparative, cohort study.
McCarter KR; Wolfgang T; Arabelovic S; Wang X; Yoshida K; Banasiak EP; Qian G; Kowalski EN; Vanni KMM; LeBoeuf NR; Buchbinder EI; Gedmintas L; MacFarlane LA; Rao DA; Shadick NA; Gravallese EM; Sparks JA
Lancet Rheumatol; 2023 May; 5(5):e274-e283. PubMed ID: 37841635
[TBL] [Abstract][Full Text] [Related]
3. Risk of Toxicity After Initiating Immune Checkpoint Inhibitor Treatment in Patients With Rheumatoid Arthritis.
Efuni E; Cytryn S; Boland P; Niewold TB; Pavlick A; Weber J; Sandigursky S
J Clin Rheumatol; 2021 Oct; 27(7):267-271. PubMed ID: 31977647
[TBL] [Abstract][Full Text] [Related]
4. Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.
Cunningham-Bussel A; Wang J; Prisco LC; Martin LW; Vanni KMM; Zaccardelli A; Nasrallah M; Gedmintas L; MacFarlane LA; Shadick NA; Awad MM; Rahma O; LeBoeuf NR; Gravallese EM; Sparks JA
Arthritis Rheumatol; 2022 Mar; 74(3):527-540. PubMed ID: 34397169
[TBL] [Abstract][Full Text] [Related]
5. Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial.
Lillegraven S; Paulshus Sundlisæter N; Aga AB; Sexton J; Olsen IC; Fremstad H; Spada C; Madland TM; Høili CA; Bakland G; Lexberg Å; Hansen IJW; Hansen IM; Haukeland H; Ljoså MA; Moholt E; Uhlig T; Solomon DH; van der Heijde D; Kvien TK; Haavardsholm EA
JAMA; 2021 May; 325(17):1755-1764. PubMed ID: 33944875
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy.
Halle BR; Betof Warner A; Zaman FY; Haydon A; Bhave P; Dewan AK; Ye F; Irlmeier R; Mehta P; Kurtansky NR; Lacouture ME; Hassel JC; Choi JS; Sosman JA; Chandra S; Otto TS; Sullivan R; Mooradian MJ; Chen ST; Dimitriou F; Long G; Carlino M; Menzies A; Johnson DB; Rotemberg VM
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34635495
[TBL] [Abstract][Full Text] [Related]
7. Safety of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease.
Alexander S; Swami U; Kaur A; Gao Y; Fatima M; Ginn MM; Stein JE; Grivas P; Zakharia Y; Singh N
Ann Transl Med; 2021 Jun; 9(12):1033. PubMed ID: 34277833
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for flare and treatment of disease flares during pregnancy in rheumatoid arthritis and axial spondyloarthritis patients.
van den Brandt S; Zbinden A; Baeten D; Villiger PM; Østensen M; Förger F
Arthritis Res Ther; 2017 Mar; 19(1):64. PubMed ID: 28320445
[TBL] [Abstract][Full Text] [Related]
9. Flares in Patients with Rheumatoid Arthritis after Total Hip and Total Knee Arthroplasty: Rates, Characteristics, and Risk Factors.
Goodman SM; Bykerk VP; DiCarlo E; Cummings RW; Donlin LT; Orange DE; Hoang A; Mirza S; McNamara M; Andersen K; Bartlett SJ; Szymonifka J; Figgie MP
J Rheumatol; 2018 May; 45(5):604-611. PubMed ID: 29545451
[TBL] [Abstract][Full Text] [Related]
10. Flares in rheumatoid arthritis: frequency and management. A report from the BRASS registry.
Bykerk VP; Shadick N; Frits M; Bingham CO; Jeffery I; Iannaccone C; Weinblatt M; Solomon DH
J Rheumatol; 2014 Feb; 41(2):227-34. PubMed ID: 24334643
[TBL] [Abstract][Full Text] [Related]
11. Immune-related adverse events in patients with pre-existing autoimmune rheumatologic disease on immune checkpoint inhibitor therapy.
Lusa A; Alvarez C; Saxena Beem S; Schwartz TA; Ishizawar R
BMC Rheumatol; 2022 Nov; 6(1):64. PubMed ID: 36345032
[TBL] [Abstract][Full Text] [Related]
12. Two-year Outcomes of Infliximab Discontinuation in Patients with Rheumatoid Arthritis: A Retrospective Analysis from a Single Center.
Takai C; Ito S; Kobayashi D; Nemoto T; Lee H; Abe A; Otani H; Nakazono K; Murasawa A; Ishikawa H
Intern Med; 2020; 59(16):1963-1970. PubMed ID: 32801270
[TBL] [Abstract][Full Text] [Related]
13. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
[TBL] [Abstract][Full Text] [Related]
14. Flares in Rheumatoid Arthritis Patients with Low Disease Activity: Predictability and Association with Worse Clinical Outcomes.
Bechman K; Tweehuysen L; Garrood T; Scott DL; Cope AP; Galloway JB; Ma MHY
J Rheumatol; 2018 Nov; 45(11):1515-1521. PubMed ID: 30173149
[TBL] [Abstract][Full Text] [Related]
15. Use of immune checkpoint inhibitors in cancer patients with pre-existing sarcoidosis.
Kim ST; Pundole X; Dadu R; Lambotte O; Ramos-Casals M; Suarez-Almazor ME
Immunotherapy; 2021 Apr; 13(6):465-475. PubMed ID: 33641345
[TBL] [Abstract][Full Text] [Related]
16. Immune-related adverse events after immune checkpoint inhibitor exposure in adult cancer patients with pre-existing autoimmune diseases.
Pizuorno Machado A; Shatila M; Liu C; Wang J; Altan M; Zhang HC; Thomas A; Wang Y
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6341-6350. PubMed ID: 36752908
[TBL] [Abstract][Full Text] [Related]
17. Treatment of immune checkpoint inhibitor-induced inflammatory arthritis.
Jeurling S; Cappelli LC
Curr Opin Rheumatol; 2020 May; 32(3):315-320. PubMed ID: 32168068
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study.
Ladouceur A; Barnetche T; Mouterde G; Tison A; Bitoun S; Prey S; Dutriaux C; Gerard E; Pham-Ledard A; Beylot-Barry M; Zysman M; Veillon R; Domblides C; Daste A; Gross-Goupil M; Sionneau B; Lefort F; Larroquette M; Richez C; Truchetet ME; Schaeverbeke T; Kostine M
RMD Open; 2023 Nov; 9(4):. PubMed ID: 38030233
[TBL] [Abstract][Full Text] [Related]
19. Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs).
Adami G; Fassio A; Rossini M; Bertelle D; Pistillo F; Benini C; Viapiana O; Gatti D
RMD Open; 2023 Jan; 9(1):. PubMed ID: 36599630
[TBL] [Abstract][Full Text] [Related]
20. Correlates of Successful Rheumatoid Arthritis Flare Management: Clinician-driven Treatment, Home-based Strategies, and Medication Change.
Mahmoud TG; Huang J; Frits M; Iannaccone C; Bykerk V; Bingham CO; Weinblatt M; Shadick NA
J Rheumatol; 2020 Mar; 47(3):333-340. PubMed ID: 31203222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
